Skip to content

Free cash flow at other companies

UroGen Pharma logo
UroGen PharmaURGN
-$45.37M-7.8%
Nuvation Bio logo
Nuvation BioNUVB
$5.02M+112%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%
Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%

Valuation

See full
Market cap$1.79B+318%
Enterprise value$1.71B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s free cash flow?
Tyra Biosciences, Inc. (TYRA) reported free cash flow of -$32.66M in Q1 2026.
How has Tyra Biosciences, Inc.'s free cash flow changed year-over-year?
Tyra Biosciences, Inc.'s free cash flow decreased by 28.2% year-over-year, from -$25.47M to -$32.66M.
What is the long-term trend for Tyra Biosciences, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s free cash flow has grown at a 40.6% compound annual growth rate (CAGR), from -$24.41M to -$95.28M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.